Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
The yellow fever vaccine (live, lyophilized) from the M.P. Chumakov Institute is a live attenuated vaccine containing the 17D-213 substrain of the yellow fever virus. It is prepared in embryonated chicken eggs and formulated as a lyophilized (freeze-dried) powder for reconstitution. As one of only four WHO-prequalified yellow fever vaccines globally (certified since 2009), it is a critical component of international immunization programs, including UNICEF's Eliminating Yellow Fever Epidemics (EYE) Strategy, supporting vaccination in over 50 countries. The vaccine works by inducing long-term protective immunity through the production of neutralizing antibodies and cellular immune responses against the yellow fever virus.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on yellow fever vaccine (Chumakov Federal Scientific Center).